EP3505520A1 - Methods useful in the synthesis of halichondrin b analogs - Google Patents

Methods useful in the synthesis of halichondrin b analogs Download PDF

Info

Publication number
EP3505520A1
EP3505520A1 EP18209462.3A EP18209462A EP3505520A1 EP 3505520 A1 EP3505520 A1 EP 3505520A1 EP 18209462 A EP18209462 A EP 18209462A EP 3505520 A1 EP3505520 A1 EP 3505520A1
Authority
EP
European Patent Office
Prior art keywords
eribulin
pharmaceutically acceptable
acceptable salt
acetonitrile
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18209462.3A
Other languages
German (de)
English (en)
French (fr)
Inventor
Bryan M. Lewis
Yongbo Hu
Huiming Zhang
Hiroyuki Chiba
Yuki Komatsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of EP3505520A1 publication Critical patent/EP3505520A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to methods useful in the synthesis of analogs of halichondrin B, in particular ER-086526, referred to under its generic name eribulin throughout the following specification.
  • Eribulin (marketed under the trade name HALAVEN® as eribulin mesylate), a nontaxane microtubule dynamics inhibitor, is a structurally simplified, synthetic analog of the marine natural product halichondrin B.
  • Methods for the synthesis of eribulin and other halichondrin B analogs are described in U.S. Patent Nos. 6,214,865 , 6,365,759 , 6,469,182 , 7,982,060 , and 8,148,554 , the syntheses of which are incorporated herein by reference. New methods for the synthesis of halichondrin B analogs, in particular eribulin and eribulin mesylate, are desirable.
  • the present invention features improved methods useful for the synthesis of analogs of halichondrin B, such as eribulin and pharmaceutically acceptable salts thereof (e.g., eribulin mesylate).
  • the invention features a method of preparing an intermediate in the synthesis of eribulin including reacting a compound having formula (I): wherein each of R 1 , R 2 , R 3 , R 4 , and R 5 is independently a silyl group (e.g., trimethylsilyl (TMS), triethylsilyl (TES), t -butyldimethylsilyl (TBS), t -butyldiphenylsilyl (TBDPS), triisopropylsilyl (TIPS), or triphenylsilyl (TPS)), with a fluoride source (e.g., tetrabutylammonium fluoride) in a solvent including an amide, e.g., a N,N C1-C6 dialkyl C1-C6 alkyl amide or N C1-C6 alkyl C2-C6 lactam, such as N,N -dimethylacetamide (e.
  • ER-811475 may be produced in a mixture with its C12 stereoisomer, ER-811474:
  • the method may further include adding a mixture of acetonitrile and water to increase the yield of ER-811475.
  • each of R 1 , R 2 , R 3 , R 4 , and R 5 is t -butyldimethylsilyl (TBS).
  • the invention further features a method of preparing an intermediate in the synthesis of eribulin including reacting (e.g., in ethanol) ER-811475 with a conjugate acid of imidazole (e.g., imidazole hydrochloride) to produce the intermediate ER-076349: ER-811475 can be produced by any of the methods provided herein.
  • a conjugate acid of imidazole e.g., imidazole hydrochloride
  • the invention features a method of preparing an intermediate in the synthesis of eribulin.
  • This method includes reacting (e.g., in acetonitrile) ER-076349 with a sulfonylating reagent, e.g., tosyl chloride, in the presence of a metal catalyst (e.g., dibutyltin oxide) to produce the intermediate: wherein R 6 is sulfonyl, e.g., ER-082892.
  • the reacting may occur above 0°C.
  • ER-076349 can be produced by any of the methods provided herein.
  • the methods may also include addition of a base, e.g., a C1-6 trialkylamine, such as triethylamine or N,N -diisopropylethylamine.
  • the invention also features a method of producing eribulin.
  • This method includes producing intermediate ER-811475 by any one of the foregoing methods, ketalizing ER-811475 to produce the intermediate ER-076349, and aminating ER-076349 to produce eribulin (ER-086526):
  • the step of ketalizing ER-811475 may include converting ER-811475 to ER-076349 according to any of the methods provided herein.
  • the step of aminating ER-076349 to produce eribulin may include converting ER-076349 to ER-082892 according to any of the methods provided herein.
  • the invention further features an alternative method of producing eribulin.
  • This method includes producing intermediate ER-076349 by any one of the foregoing methods and aminating ER-076349 to produce eribulin.
  • the step of aminating ER-076349 to produce eribulin may include converting ER-076349 to ER-082892 according to any of the methods provided herein.
  • the invention features yet another method of producing eribulin.
  • This method includes producing intermediate ER-082892 by any of the methods provided herein and aminating ER-082892 to produce eribulin.
  • Any method of producing eribulin may further include salifying eribulin to produce a pharmaceutically acceptable salt of eribulin (e.g., eribulin mesylate).
  • the invention further features a method of manufacturing a pharmaceutical product including eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate).
  • This method includes producing or directing the production of eribulin or a pharmaceutically acceptable salt thereof by any one of the foregoing methods and processing or directing the processing of eribulin or a pharmaceutically acceptable salt thereof into a pharmaceutical product including eribulin or a pharmaceutically acceptable salt thereof, thereby manufacturing a pharmaceutical product including eribulin or a pharmaceutically acceptable salt thereof.
  • the processing step can include one or more of formulating eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate); processing eribulin or a pharmaceutically acceptable salt thereof into a drug product; combining eribulin or a pharmaceutically acceptable salt thereof with a second component (e.g., an excipient or pharmaceutically acceptable carrier); lyophilizing eribulin or a pharmaceutically acceptable salt thereof; combining a first and second batch of eribulin or a pharmaceutically acceptable salt thereof to provide a third larger batch; disposing eribulin or a pharmaceutically acceptable salt thereof into a container (e.g., a gas or liquid tight container); packaging eribulin or a pharmaceutically acceptable salt thereof; associating a container including eribulin or a pharmaceutically acceptable salt thereof with a label; and shipping or moving eribulin or a pharmaceutically acceptable salt thereof to a different location.
  • a container e.g., a gas
  • a number following an atomic symbol indicates the total number of atoms of that element that are present in a particular chemical moiety.
  • other atoms such as hydrogen atoms, or substituent groups, as described herein, may be present, as necessary, to satisfy the valences of the atoms.
  • an unsubstituted C2 alkyl group has the formula -CH 2 CH 3 .
  • a reference to the number of oxygen, nitrogen, or sulfur atoms in a heteroaryl group only includes those atoms that form a part of a heterocyclic ring.
  • alkyl is meant a straight or branched chain saturated cyclic (i.e., cycloalkyl) or acyclic hydrocarbon group of from 1 to 12 carbons, unless otherwise specified.
  • exemplary alkyl groups include C1-C8, C1-C6, C1-C4, C2-C7, C3-C12, and C3-C6 alkyl.
  • Specific examples include methyl, ethyl, 1-propyl, 2-propyl (i.e., isopropyl), 2-methyl-1-propyl (i.e., iso -butyl), 1-butyl, 2-butyl, 1,1-dimethylethyl (i.e., tert -butyl) and the like.
  • alkyl groups are optionally substituted with halogen, alkoxy, aryloxy, arylalkyloxy, oxo, alkylthio, alkylenedithio, alkylamino, [alkenyl]alkylamino, [aryl]alkylamino, [arylalkyl]alkylamino, dialkylamino, silyl, sulfonyl, cyano, nitro, carboxyl, or azido.
  • alkylamino is meant -NHR, wherein R is alkyl.
  • alkenyl]alkylamino is meant -NRR', wherein R is alkyl, and R' is alkenyl.
  • [aryl]alkylamino is meant -NRR', wherein R is alkyl, and R' is aryl.
  • [arylalkyl]alkylamino is meant-NRR', wherein R is alkyl, and R' is arylalkyl.
  • dialkylamino is meant -NR 2 , wherein each R is alkyl, selected independently.
  • alkylene is meant a divalent alkyl group.
  • Alkylene groups used in any context herein, are optionally substituted in the same manner as alkyl groups.
  • an unsubstituted C1 alkylene group is -CH 2 -.
  • alkylenedithio is meant -S-alkylene-S-.
  • alkylthio is meant -SR, wherein R is alkyl.
  • alkenyl is meant a straight or branched chain cyclic or acyclic hydrocarbon group of, unless otherwise specified, from 2 to 12 carbons and containing one or more carbon-carbon double bonds.
  • alkenyl groups include C2-C8, C2-C7, C2-C6, C2-C4, C3-C12, and C3-C6 alkenyl. Specific examples include ethenyl (i.e., vinyl), 1-propenyl, 2-propenyl (i.e., allyl), 2-methyl-1-propenyl, 1-butenyl, 2-butenyl (i.e., crotyl), and the like.
  • Alkenyl groups, used in any context herein are optionally substituted in the same manner as alkyl groups. Alkenyl groups, used in any context herein, may also be substituted with an aryl group.
  • alkoxy is meant -OR, wherein R is alkyl.
  • aryl is meant a monocyclic or multicyclic ring system having one or more aromatic rings, wherein the ring system is carbocyclic or heterocyclic.
  • Heterocyclic aryl groups are also referred to as heteroaryl groups.
  • a heteroaryl group includes 1 to 4 atoms selected independently from O, N, and S.
  • Exemplary carbocyclic aryl groups include C6-C20, C6-C15, C6-C10, C8-C20, and C8-C15 aryl.
  • a preferred aryl group is a C6-10 aryl group.
  • carbocyclic aryl groups include phenyl, indanyl, indenyl, naphthyl, phenanthryl, anthracyl, and fluorenyl.
  • exemplary heteroaryl groups include monocylic rings having from 1 to 4 heteroatoms selected independently from O, N, and S and from 1 to 6 carbons (e.g., C1-C6, C1-C4, and C2-C6).
  • Monocyclic heteroaryl groups preferably include from 5 to 9 ring members.
  • Other heteroaryl groups preferably include from 4 to 19 carbon atoms (e.g., C4-C10).
  • heteroaryl groups include pyridinyl, quinolinyl, dihydroquinolinyl, isoquinolinyl, quinazolinyl, dihydroquinazolyl, and tetrahydroquinazolyl.
  • aryl groups used in any context herein, are optionally substituted with alkyl, alkenyl, aryl, arylalkyl, halogen, alkoxy, aryloxy, arylalkyloxy, oxo, alkylthio, alkylenedithio, alkylamino, [alkenyl]alkylamino, [aryl]alkylamino, [arylalkyl]alkylamino, dialkylamino, silyl, sulfonyl, cyano, nitro, carboxyl, or azido.
  • arylalkyl is meant -R'R", wherein R' is alkylene, and R" is aryl.
  • arylalkyloxy is meant -OR, wherein R is arylalkyl.
  • aryloxy is meant -OR, wherein R is aryl.
  • carboxyl is meant -C(O)OH, in free acid, ionized, or salt form.
  • fluoride source is meant a compound that can be a source of soluble fluoride ion (i.e., F - ) (e.g., to remove silyl ether hydroxyl protecting groups), exemplary fluoride sources include, ammonium fluoride, benzyltriethylammonium fluoride, cesium fluoride (i.e., CsF), 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (i.e., Selectfluor®), hydrofluoric acid (i.e., HF), poly[4-vinylpyridinium poly(hydrogen fluoride)], potassium fluoride (i.e., KF), pyridine hydrogen fluoride (i.e., HF-pyridine), sodium fluoride (i.e., NaF), tetrabutylammonium fluoride (i.e., TB
  • halogen is meant fluoro, chloro, bromo, or iodo.
  • lactam is meant a cyclic amide, wherein the ring consists of carbon atoms and one nitrogen atom.
  • leaving group is meant a group that is displaced during a chemical reaction. Suitable leaving groups are well known in the art, e.g., see, Advanced Organic Chemistry, March, 4th Ed., pp. 351-357, John Wiley and Sons, N.Y. (1992 ).
  • Such leaving groups include halogen, C1-C12 alkoxy (e.g., C1-C8, C1-C6, C1-C4, C2-C7, and C3-C6 alkoxy), C1-C12 alkylsulfonate (e.g., C1-C8, C1-C6, C1-C4, C2-C7, C3-C12, and C3-C6 alkylsulfonate), C2-C12 alkenylsulfonate (e.g., C2-C8, C2-C6, C2-C4, C3-C12, and C3-C6 alkenylsulfonate), carbocyclic C6-C20 arylsulfonate (e.g., C6-C15, C6-C10, C8-C20, and C8-C15 arylsulfonate), C4-C19 heteroarylsulfonate (e.g., C4-C10 heteroarylsulfonate),
  • Alkylsulfonates, alkenylsulfonates, arylsulfonates, heteroarylsulfonates, arylalkylsulfonates, and heteroarylalkylsulfonates can be optionally substituted with halogen (e.g., chloro, iodo, bromo, or fluoro), alkoxy (e.g., C1-C6 alkoxy), aryloxy (e.g., C6-C15 aryloxy, C4-C19 heteroaryloxy, and C1-C6 heteroaryloxy), oxo, alkylthio (e.g., C1-C6 alkylthio), alkylenedithio (e.g., C1-C6 alkylenedithio), alkylamino (e.g., C1-C6 alkylamino), [alkenyl]alkylamino (e.g., [(C2-C6)alken
  • Alkenylsulfonates can be optionally substituted with carbocyclic aryl (e.g., C6-C15 aryl), monocyclic C1-C6 heteroaryl, or C4-C19 heteroaryl (e.g., C4-C10 heteroaryl).
  • Arylsulfonates can be optionally substituted with alkyl (e.g., C1-C6 alkyl) or alkenyl (e.g., C2-C6 alkenyl).
  • any heteroaryl group present in a leaving group has from 1 to 4 heteroatoms selected independently from O, N, and S.
  • Suitable leaving groups include chloro, iodo, bromo, fluoro, methanesulfonate (mesylate), 4-toluenesulfonate (tosylate), trifluoromethanesulfonate (triflate, OTf), nitro-phenylsulfonate (nosylate), and bromo-phenylsulfonate (brosylate). Leaving groups may also be further substituted as is known in the art.
  • pharmaceutically acceptable salt is meant a salt within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and the like and commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in Berge et al., J. Pharmaceutical Sciences 66:1-19, 1977 and Pharmaceutical Salts: Properties, Selection, and Use, (Eds. P.H. Stahl and C.G. Wermuth), Wiley-VCH, 2008 .
  • Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide (i.e., HBr), hydrochloride (i.e., HCI), hydroiodide (i.e., HI), 2-hydroxyethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate (i.e., mesylate), 2-naphthalenesulf
  • silyl is meant -SiR 3 , wherein each R is independently alkyl, alkenyl, aryl, or arylalkyl.
  • silyl groups include tri(C1-C6 alkyl)silyl, tri(C6-C10 aryl or C1-C6 heteroaryl)silyl, di(C6-C10 aryl or C1-C6 heteroaryl)(C1-C6 alkyl)silyl, and (C6-C10 aryl or C1-C6 heteroaryl)di(C1-C6 alkyl)silyl.
  • silyl group when a silyl group includes two or more alkyl, alkenyl, aryl, heteroaryl, or arylalkyl groups, these groups are independently selected. As defined herein, any heteroaryl group present in a silyl group has from 1 to 4 heteroatoms selected independently from O, N, and S. Silyl groups are known in the art, e.g., as described in Greene's Protective Groups in Organic Synthesis, Wiley-Interscience, 4th Edition, 2006 .
  • silyl groups include trimethylsilyl (TMS), triethylsilyl (TES), t -butyldimethylsilyl (TBS), t -butyldiphenylsilyl (TBDPS), triisopropylsilyl (TIPS), and triphenylsilyl (TPS) ethers.
  • Silyl groups may be substituted as is known in the art; for example, aryl and arylalkyl groups, such as phenyl, benzyl, naphthyl, or pyridinyl, can be substituted with C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, or halogen.
  • Alkyl groups such as methyl, ethyl, isopropyl, n -propyl, t -butyl, n -butyl, and sec-butyl, and alkenyl groups, such as vinyl and allyl, can also be substituted with oxo, arylsulfonyl, halogen, and trialkylsilyl groups.
  • sulfonyl is meant -S(O) 2 R, wherein R is alkyl, alkenyl, aryl, arylalkyl, or silyl.
  • R is C1-C12 alkyl (e.g., C1-C8, C1-C6, C1-C4, C2-C7, C3-C12, and C3-C6 alkyl), C2-C12 alkenyl (e.g., C2-C8, C2-C6, C2-C4, C3-C12, and C3-C6 alkenyl), carbocyclic C6-C20 aryl (e.g., C6-C15, C6-C10, C8-C20, and C8-C15 aryl), monocyclic C1-C6 heteroaryl (e.g., C1-C4 and C2-C6 heteroaryl), C4-C19 heteroaryl (e.g., C4-C10 heteroaryl
  • any heteroaryl group present in a sulfonyl group has from 1 to 4 heteroatoms selected independently from O, N, and S.
  • exemplary sulfonyl groups include tosyl, triflyl, and mesyl.
  • the present invention provides methods for the synthesis of halichondrin B analogs.
  • the methods are useful for the synthesis of eribulin and pharmaceutically acceptable salts thereof:
  • Compounds of formula (I): can be synthesized using methods known in the art (e.g., as described in U.S. Patent Nos. 6,214,865 , 6,365,759 , 6,469,182 , 7,982,060 , and 8,148,554 , International Publication Nos. WO 99/65894 , WO 2005/118565 , and WO 2011/094339 , Chase et al. Syn. Lett. 2013; 24(3):323-326 , Austad et al. Syn. Lett. 2013; 24(3):327-332 , and Austad et al. Syn. Lett. 2013; 24(3):333-337 , the syntheses of which are incorporated herein by reference).
  • the C14-C35 portion (e.g., ER-804028) of the molecule is coupled to the C1-C13 portion (e.g., ER-803896) to produce the C1-C35 acyclic intermediate (e.g., ER-804029), and additional reactions are carried out to produce a compound of formula (I) (e.g., ER-118046) as shown in Scheme 1:
  • deprotonation e.g., by lithiation
  • C14-C35 sulfone fragment i.e., ER-804028
  • C1-C13 aldehyde fragment i.e., ER-803896
  • ER-804029 a mixture of diastereomeric alcohols
  • Step A deprotection of the silyl ether hydroxyl protecting groups (i.e., R 1 , R 2 , R 3 , R 4 , and R 5 ) of a compound of formula (I) followed by equilibration furnishes ER-811475 (Step A). Ketalization of ER-811475 provides ER-076349 (Step B). Activation of the C35 primary alcohol (e.g., as the C35 tosylate) resulting in a compound of formula (II), wherein X is a leaving group (e.g., halogen, mesylate, or tosylate) (Step C), followed by introduction of the amine functionality, provides eribulin (Step D).
  • X is a leaving group (e.g., halogen, mesylate, or tosylate)
  • Step A Conversion of a compound of formula (I) to ER-811475
  • a fluoride source e.g., tetrabutylammonium fluoride
  • a conjugate acid of imidazole e.g., imidazole hydrochloride
  • Method A2 Deprotection with Fluoride Source in an Amide, e.g., DMAC
  • a fluoride source e.g., tetrabutylammonium fluoride
  • a conjugate acid of imidazole e.g., imidazole hydrochloride
  • an amide e.g., N,N -dimethylacetamide (DMAC)
  • solvent e.g., a mixture of tetrahyrofuran (THF) and DMAC
  • DMAC N,N -dimethylacetamide
  • the addition of DMAC as co-solvent in the reaction results in improved selectivity at C12 (e.g., 18:1 vs. 4:1) and shortened reaction time (e.g., 1-2 days from 7-10 days).
  • amides include an N,N C1-C6 dialkyl C1-C6 alkyl amide or N C1-C6 alkyl C2-C6 lactam, such as N,N-dimethylformamide, N-methyl 2-pyrrolidone, N,N-diethylacetamide, or N,N-dimethylpropionamide may also be employed.
  • Step B Ketalization of ER-811475 to ER-076349
  • Ketalization of ER-811475 (e.g., in dichloromethane) with a conjugate acid of pyridine (e.g., pyridinium p-toluenesulfonate (PPTS)), followed by crystallization from acetonitrile and water, provides ER-076349.
  • a conjugate acid of pyridine e.g., pyridinium p-toluenesulfonate (PPTS)
  • PPTS pyridinium p-toluenesulfonate
  • Conversion of ER-811475 to ER-076349 can be achieved through ketalization of ER-811475 (e.g., in ethanol) with a conjugate acid of imidazole (e.g., imidazole hydrochloride), followed by column chromatography.
  • a conjugate acid of imidazole e.g., imidazole hydrochloride
  • Replacing PPTS with imidazole hydrochloride results in a decrease of isomerization at C12 during post-processing (e.g., concentration of the reaction mixture).
  • Changing of the solvent from dichloromethane to ethanol results in a more environmentally favorable process.
  • Step C Activation of ER-076349 to a compound of formula (II)
  • ER-076349 e.g., in dichloromethane
  • tosyl chloride and a base e.g., pyridine
  • a base e.g., pyridine
  • ER-076349 e.g., in dichloromethane
  • Ts 2 O 4-toluenesulfonic anhydride
  • base e.g., a combination of 2,4,6-collidine and pyridine
  • Reacting ER-076349 e.g., in dichloromethane
  • mesyl chloride and a base e.g., 2,4,6-collidine
  • a base e.g., 2,4,6-collidine
  • ER-076349 e.g., in acetonitrile
  • a base e.g., a C1-C6 trialkylamine, such as triethylamine and N,N- diisopropylethylamine
  • a catalyst e.g., dibutyltin oxide
  • dibutyltin oxide makes the process more robust (e.g., reduces reaction sensitivity to moisture) and improves process operational efficiency (e.g., by elimination of an azeotropic drying step).
  • Replacing pyridine and/or collidine with N,N -diisopropylethylamine and the addition of dibutyltin oxide as a catalyst provide an improvement in selectivity for primary alcohol (e.g., the mono-tosylation:di-tosylation ratio improved from 96:4 to 99.8:0.2).
  • the replacement of dichloromethane with acetonitrile as solvent results in a more environmentally favorable process, and the change in temperature from -10°C to 26 °C - 28°C increases operational efficiency and yield.
  • Step D Amination of a compound of formula (II) to eribulin
  • the amination of a compound of formula (II) can be accomplished through treatment with alcoholic ammonium hydroxide resulting in cyclization to an epoxide in situ that reacts further with ammonia to provide eribulin.
  • alcoholic ammonium hydroxide resulting in cyclization to an epoxide in situ that reacts further with ammonia to provide eribulin.
  • Replacement of the Staudinger route with the epoxide opening route results in the elimination of the use of hazardous reagents and an increase in operational efficiency.
  • eribulin mesylate can be formed by methods known in the art (e.g., in situ during the final isolation and purification of the compound or separately by reacting the free base group with a suitable acid).
  • eribulin is treated with a solution of methanesulfonic acid (i.e., MsOH) and ammonium hydroxide in water and acetonitrile. The mixture is concentrated. The residue is dissolved in dichloromethane-pentane, and the solution is added to anhydrous pentane. The resulting precipitate is filtered and dried under high vacuum to provide eribulin mesylate, as shown in Scheme 13.
  • Step A Conversion of ER-118046 to ER-811475
  • ER-811475 (1 R ,2 S ,3 S ,4 S ,5 S ,6 RS ,11 S ,14S,17S,19 R ,21 R ,23 S ,25 R ,26 R ,27 S ,31 R ,34 S )-25-[(2 S )-2,3-Dihydroxypropyl]-2,5-dihydroxy-26-methoxy-19-methyl-13,20-bis(methylene)-24,35,36,37,38,39-hexaoxaheptacyclo[29.3.1.13,6.14,34.111,14.117,21.023,27]nonatriacontane-8,29-dione
  • reaction intermediate C34/C35-diol After the residual level of the reaction intermediate C34/C35-diol reached 3% or below, acetonitrile (608 mL) and water (203 mL) were added. The mixture was stirred at 16 °C to 18 °C for 45 hours until the residual level of free pentaol came down to below 5%.
  • the reaction mixture including ER-811475/ER-811474 (a mixture of two diastereomers 18:1) could be used for the next stage without further purification.
  • Step B Ketalization of ER-811475 to ER-076349
  • ER-811475 in a mixture with ER-811474 (0.329 kg, 0.439 mol, 1 eq) was dissolved in dichloromethane (DCM; 7.7 kg) and treated with a pyridinium p-toluenesulfonate (PPTS; 0.607 kg, 2.42 mol, 5.5 eq) solution in dichloromethane (1.7 kg) at 10-20 °C.
  • PPTS pyridinium p-toluenesulfonate
  • the resulting mixture was stirred at 10-20 °C.
  • the major diastereomer reacted to provide diol ER-076349, and the minor diastereomer ER-811474 remained unreacted.
  • the column was eluted sequentially with: (1) methyl t-butyl ether (125 L), (2) 96% v/v methyl t-butyl ether in acetonitrile (125 L), (3) 50% v/v methyl t-butyl ether in acetonitrile (250 L), and (4) acetonitrile (225 L). Desired fractions were combined, concentrated in vacuo ⁇ 35 °C, and azeotroped in vacuo with acetonitrile (4.6 kg) ⁇ 35 °C.
  • ER-811475 in a mixture with ER-811474, a solution of imidazole HCI (85.5 g) in water (68 mL) was added. The solution was concentrated in vacuo at 28 °C or below. The residue was dissolved in EtOH (2.69 kg). The resulting mixture was stirred at 21 °C to 24 °C for 43 hours. The major diastereomer (ER-811475) reacted to provide diol ER-076349, and the minor diastereomer (ER-811474) remains unreacted. The reaction was monitored for a disappearance of ER-811475 by HPLC. After the residual level of ER-811475 reached below 1%, the solution was concentrated in vacuo at 37 °C or below.
  • the aqueous layers were combined and extracted with toluene (1.18 kg) and THF (1.20 kg).
  • the aqueous layer was drained, and the organic layer was combined with the first extract.
  • the combined organic layers were concentrated in vacuo at 37 °C or below.
  • the column was eluted sequentially with methyl t-butyl ether (40.8 L), 95% v/v methyl t-butyl ether in acetonitrile (24.9 L), 40% v/v methyl t-butyl ether in acetonitrile (83.6 L), and acetonitrile (76.3 L) to remove the unreacted intermediates, the reaction impurities, and the carryover impurities from ER-804028. Desired fractions were combined and concentrated in vacuo at 32 °C or below to give ER-076349 (assay 62.02g, yield over two steps 84.0%). The residue was azeotroped in vacuo with acetonitrile (0.533 kg) at 29 °C or below and could be used for the next stage without further purification.
  • Steps C and D Conversion of ER-076349 to eribulin:
  • ER-076349 (0.259 kg, 0.354 mol, 1 eq) was dissolved in toluene (4.7 kg) and azeotroped in vacuo at ⁇ 25 °C. The residue was diluted with toluene (4.5 kg) to give a toluene solution for monitoring of water content. Water content was measured by Karl-Fischer (KF) titration method. If the KF value was > 125 ppm, the solution was azeotroped in vacuo at ⁇ 25 °C and diluted with toluene (4.5 kg) until the water content came down to ⁇ 125 ppm.
  • KF Karl-Fischer
  • the reaction mixture was quenched by the addition of water (1.0 kg). The mixture was warmed up, and then isopropyl alcohol (IPA) (20.5 kg) and ammonium hydroxide (NH 4 OH; 25.7 kg) were added consecutively at 10-30 °C. Upon complete consumption of the epoxide (target ⁇ 0.85%; add extra NH 4 OH if necessary), the reaction mixture was concentrated in vacuo at ⁇ 30 °C.
  • IPA isopropyl alcohol
  • NH 4 OH ammonium hydroxide
  • dichloromethane (20.7 kg) and a sufficient amount of buffer solution of NaHCO 3 /Na 2 CO 3 /water (9/9/182 w/w/w; not more than 5.166 kg) were added and extracted.
  • the organic layer was separated, and the aqueous layer was extracted with dichloromethane (8.6 kg).
  • the organic layer was separated and combined with the first extract.
  • the combined organic layers were concentrated in vacuo at ⁇ 30 °C.
  • the concentrate was diluted with acetonitrile (4.0 kg) and then loaded onto silica gel column which was preequilibrated with acetonitrile (200 L).
  • the column was eluted sequentially with: (1) acetonitrile (100 L), (2) 90.0/7.5/2.5 v/v/v acetonitrile/water/200 mM aqueous NH 4 OAc (152.4 L), (3) 85.8/11.7/2.5 v/v/v acetonitrile/water/200 mM aqueous NH 4 OAc (152.4 L), (4) 83.5/14.0/2.5 v/v/v acetonitrile/water/200 mM aqueous NH 4 OAc (152.6 L), and (5) 80.0/17.6/2.4 v/v/v acetonitrile/water/200 mM aqueous NH 4 OAc (>100.2 L).
  • Desired fractions were combined and concentrated in vacuo at ⁇ 40 °C while maintaining the internal pH at 5.5-9.0 by adding NH 4 OH.
  • dichloromethane (13.9 kg) and a sufficient amount of buffer solution of NaHCO 3 /Na 2 CO 3 /water (9/9/182 w/w/w; not more than 15.51 kg) were added and extracted.
  • the organic layer was separated, and the aqueous layer was extracted with dichloromethane (8.7 kg).
  • the organic layer was separated and combined with the first extract.
  • the combined organic layers were concentrated in vacuo at ⁇ 30 °C.
  • the residue was dissolved in 75% v/v anhydrous dichloromethane in n-pentane (6.12 kg) and filtered.
  • the filtrate was concentrated in vacuo at ⁇ 30 °C, diluted with acetonitrile (2.1 kg), and concentrated in vacuo at ⁇ 35 °C to give eribulin (75-95% yield
  • the diol ER-076349 (58.3 g) was dissolved in acetonitrile (935 mL). A suspension of dibutyltin oxide (0.99 g) and N,N -diisopropylethylamine (28.5 mL) in acetonitrile (117 mL) were added. A solution of TsCI (30.5 g) in acetonitrile (117 mL) was added to the reaction mixture at a rate to maintain the reaction temperature at 26 °C to 28 °C, and the mixture was stirred at 26 °C to 28 °C. The reaction was monitored by HPLC for consumption of ER-076349.
  • IPA isopropyl alcohol
  • ammonium hydroxide 5.82 kg
  • dichloromethane (4.64 kg) and a sufficient amount of buffer solution of NaHCO 3 / Na 2 CO 3 / water (9/9/182 w/w/w) (530 mL) were added and extracted.
  • the organic layer was separated, and the aqueous layer was extracted with dichloromethane (1.94 kg).
  • the organic layer was separated, and combined with the first extract.
  • the combined organic layers were concentrated in vacuo at 25 °C or below.
  • the concentrate was diluted with acetonitrile (1.17 L), and then loaded onto silica gel column (5.511 kg) which was pre-equilibrated with acetonitrile (more than 55.1 L).
  • the column was eluted sequentially with acetonitrile (29.6 L), 90.0/7.5/2.5 v/v/v acetonitrile/water/200 mM aqueous NH 4 OAc (46.2 L), 85.8/11.7/2.5 v/v/v acetonitrile/water/200 mM aqueous NH 4 OAc (45.8 L), 83.5/14.0/2.5 v/v/v acetonitrile/water/200 mM aqueous NH 4 OAc (46.5 L), 80.0/17.6/2.4 v/v/v acetonitrile/water/200 mM aqueous NH 4 OAc (29.8 L) to remove the unreacted intermediates and the reaction impurities.
  • Desired fractions were combined and concentrated in vacuo at 36 °C or below while maintaining the internal pH at 5.5 to 9.0 by adding ammonium hydroxide.
  • dichloromethane (3.98 kg) and a sufficient amount of buffer solution of NaHCO 3 / Na 2 CO 3 / water (9/9/182 w/w/w) (2.02 kg) were added and extracted.
  • the organic layer was separated, and the aqueous layer was extracted with dichloromethane (2.48 kg).
  • the organic layer was separated and combined with the first extract.
  • the combined organic layers were concentrated in vacuo at 24 °C or below.
  • the residue was dissolved in 75% v/v anhydrous dichloromethane in n-pentane (1.03 L) and filtered.
  • the filtrate was concentrated in vacuo at 25 °C or below to give eribulin.
  • the residue was diluted with acetonitrile (392 mL) and dichloromethane (69 mL) to give eribulin acetonitrile/dichloromethane solution (assay 49.11g, corrected yield 85.3%).
  • the solution was concentrated in vacuo at 29 °C or below and used for the next stage.
  • ER-086526-00 (46.68 g) was dissolved in acetonitrile (591 mL) and water (31 mL) and treated with a solution of methanesulfonic acid (MsOH, 4.09 mL) and NH 4 OH (187 mL) in acetonitrile (624 mL). The mixture was concentrated in vacuo at 24 °C or below and azeotroped repeatedly with anhydrous acetonitrile (234 mL) in vacuo at 24 °C or below to remove water. The residue was dissolved in 75% v/v anhydrous dichloromethane in n -pentane (1.10 L) and filtered.
  • the filtrate was concentrated in vacuo at 24 °C or below.
  • the residue was dissolved in 50% v/v anhydrous dichloromethane in n -pentane (1.16 L), and the solution was transferred through a filter to anhydrous pentane (3.26 kg) in the separate reactor.
  • the resulting precipitate was stirred for 29 hours.
  • the precipitates were filtered, washed with n-pentane (2.92 kg), and dried under nitrogen flow in vacuo until the residual solvent levels reached the target numbers: n-pentane ⁇ 25000 ppm; 2-methylbutane ⁇ 1000 ppm; 2,2-dimethylbutane ⁇ 1000 ppm; and cyclopentane ⁇ 1000 ppm.
  • eribulin mesylate (gross 45.95 g, corrected yield 83.8%).
  • the drug substance was filled in a polytetrafluoroethylene (PTFE) bottle.
  • the PTFE bottle was packed in an aluminum laminate bag.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
EP18209462.3A 2013-12-06 2014-12-05 Methods useful in the synthesis of halichondrin b analogs Pending EP3505520A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361912714P 2013-12-06 2013-12-06
PCT/US2014/068834 WO2015085193A1 (en) 2013-12-06 2014-12-05 Methods useful in the synthesis of halichondrin b analogs
EP14866945.0A EP3077399B1 (en) 2013-12-06 2014-12-05 Methods useful in the synthesis of halichondrin b analogs

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP14866945.0A Division-Into EP3077399B1 (en) 2013-12-06 2014-12-05 Methods useful in the synthesis of halichondrin b analogs
EP14866945.0A Division EP3077399B1 (en) 2013-12-06 2014-12-05 Methods useful in the synthesis of halichondrin b analogs

Publications (1)

Publication Number Publication Date
EP3505520A1 true EP3505520A1 (en) 2019-07-03

Family

ID=53270478

Family Applications (2)

Application Number Title Priority Date Filing Date
EP18209462.3A Pending EP3505520A1 (en) 2013-12-06 2014-12-05 Methods useful in the synthesis of halichondrin b analogs
EP14866945.0A Active EP3077399B1 (en) 2013-12-06 2014-12-05 Methods useful in the synthesis of halichondrin b analogs

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP14866945.0A Active EP3077399B1 (en) 2013-12-06 2014-12-05 Methods useful in the synthesis of halichondrin b analogs

Country Status (13)

Country Link
US (4) US9303039B2 (ru)
EP (2) EP3505520A1 (ru)
JP (3) JP6443812B2 (ru)
CN (1) CN105916861B (ru)
BR (1) BR112016012237B1 (ru)
CA (1) CA2931788C (ru)
ES (1) ES2723355T3 (ru)
HU (1) HUE043088T2 (ru)
IL (4) IL245661A0 (ru)
MX (3) MX370611B (ru)
RU (1) RU2676486C1 (ru)
SG (2) SG10201805024YA (ru)
WO (1) WO2015085193A1 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2567984C (en) 2004-06-03 2014-05-20 Eisai Co., Ltd. Intermediates for the preparation of analogs of halichondrin b
CN104311571B (zh) 2007-10-03 2019-07-02 卫材R&D管理有限公司 用于合成软海绵素b类似物的中间体和方法
MX2010010902A (es) 2008-04-04 2010-12-21 Eisai R&D Man Co Ltd Analogos de halicondrina b.
CN102803254B (zh) 2010-01-26 2016-09-14 卫材R&D管理有限公司 用于软海绵素b类似物合成的呋喃并[3,2-b]吡喃衍生物
RU2710545C2 (ru) 2013-11-04 2019-12-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Реакции макроциклизации и промежуточные соединения и другие фрагменты, пригодные в получении аналогов халихондрина b
MX370611B (es) * 2013-12-06 2019-12-18 Eisai R&D Man Co Ltd Metodos utiles en la sintesis de analogos de halicondrina b.
US10556910B2 (en) 2014-06-30 2020-02-11 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
US10308661B2 (en) 2015-05-07 2019-06-04 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
MX2018009794A (es) 2016-02-12 2018-12-17 Eisai R&D Man Co Ltd Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.
CN114191428A (zh) 2016-03-02 2022-03-18 卫材研究发展管理有限公司 基于艾日布林的抗体-药物偶联物和使用方法
MX2018016329A (es) 2016-06-30 2019-09-18 Eisai R&D Man Co Ltd Reaccion de prins e intermediarios utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos.
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
TWI781163B (zh) 2017-04-05 2022-10-21 哈佛大學校長及研究員協會 巨環化合物及其用途
WO2018217894A1 (en) * 2017-05-24 2018-11-29 Eisai R&D Management Co., Ltd. Fluorine-labelled halichondrin derivatives and related methods of synthesis
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
EP3649135B1 (en) 2017-07-06 2022-12-28 President and Fellows of Harvard College Synthesis of halichondrins
CN109694379B (zh) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 用于制备艾日布林的中间体及其制备方法
WO2019099646A1 (en) 2017-11-15 2019-05-23 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
MX2020006945A (es) 2018-01-03 2020-11-09 Eisai R&D Man Co Ltd Reaccion de prins y compuestos utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos.
US20210260023A1 (en) * 2018-07-20 2021-08-26 Dr. Reddy's Laboratories Limited Purification process for preparation of eribulin and intermediates thereof
EP3864011A4 (en) * 2018-10-09 2022-06-29 Dr. Reddy's Laboratories Ltd. Process for preparation of eribulin and intermediates thereof
US20220089607A1 (en) * 2018-11-28 2022-03-24 Natco Pharma Limited Process for the preparation of high pure eribulin and its mesylate salt
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
WO2022101931A1 (en) * 2020-11-10 2022-05-19 Natco Pharma Limited Process for the preparation of eribulin and its intermediates
CN113354659B (zh) * 2021-06-08 2022-04-08 江苏慧聚药业股份有限公司 甲磺酸艾日布林的合成
CN114380840B (zh) * 2022-01-27 2024-01-26 江苏慧聚药业股份有限公司 艾日布林的合成

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065894A1 (en) 1998-06-17 1999-12-23 Eisai Co., Ltd. Macrocyclic analogs and methods of their use and preparation
US6194586B1 (en) * 1996-09-06 2001-02-27 Eli Lilly And Company Selective sulphonation of the primary alcohol of a diol containing both primary and secondary alcohols
WO2005118565A1 (en) 2004-06-03 2005-12-15 Eisai Co., Ltd. Intermediates for the preparation of halichondrin b
WO2011094339A1 (en) 2010-01-26 2011-08-04 Eisai R&D Management Co., Ltd. Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
EP2521717B1 (en) 2010-02-10 2013-05-22 Sandoz AG Method for the preparation of rivaroxaban

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU652180A1 (ru) 1975-12-16 1979-03-15 Краснодарский политехнический институт 1(Фурил-2,)-2-(2-,, формилфурил-5,, ) этилен или его метильное производное как промежуточный продукт дл синтеза фуран-2,5-дикарбоновой кислоты и способ его получени
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
TW255880B (ru) 1992-09-09 1995-09-01 Hoechst Ag
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
CN1993342A (zh) * 2004-06-03 2007-07-04 卫材株式会社 用于制备软海绵素b的中间体
US20060045846A1 (en) 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
WO2006076100A2 (en) 2004-12-09 2006-07-20 Eisai Co. Ltd. Tubulin isotype screening in cancer therapy using halichondrin b analogs
WO2008010776A1 (en) 2006-07-21 2008-01-24 Agency For Science, Technology And Research Aigialomycin d and derivatives thereof and their use in treating cancer or malaria or a microbial infection
JPWO2009014105A1 (ja) 2007-07-20 2010-10-07 株式会社山田養蜂場本社 新規カルボン酸およびそれを有効成分とする抗うつ用組成物
CN104311571B (zh) 2007-10-03 2019-07-02 卫材R&D管理有限公司 用于合成软海绵素b类似物的中间体和方法
JP5134686B2 (ja) 2007-11-16 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂアナログ合成のための新規な中間体及び前記中間体に用いるための新規な脱スルホニル化反応
MX2010010902A (es) * 2008-04-04 2010-12-21 Eisai R&D Man Co Ltd Analogos de halicondrina b.
JP5371091B2 (ja) 2009-01-23 2013-12-18 三菱レイヨン株式会社 モノスルホン酸エステルの製造方法
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
AU2012344697A1 (en) 2011-11-30 2014-07-10 Alphora Research Inc. Process for preparation of (3R)-2,4-di-leaving group-3-methylbut-1-ene
WO2013142999A1 (en) 2012-03-30 2013-10-03 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
CN105431438A (zh) 2013-07-03 2016-03-23 阿方拉研究股份有限公司 用于制备软海绵素b 的大环c1-酮基类似物的合成方法和可用于其中的中间体、包括含有-so2-(对甲苯基)基团的中间体
RU2710545C2 (ru) 2013-11-04 2019-12-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Реакции макроциклизации и промежуточные соединения и другие фрагменты, пригодные в получении аналогов халихондрина b
MX370611B (es) * 2013-12-06 2019-12-18 Eisai R&D Man Co Ltd Metodos utiles en la sintesis de analogos de halicondrina b.
US10308661B2 (en) 2015-05-07 2019-06-04 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
MX2018009794A (es) 2016-02-12 2018-12-17 Eisai R&D Man Co Ltd Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.
MX2018016329A (es) 2016-06-30 2019-09-18 Eisai R&D Man Co Ltd Reaccion de prins e intermediarios utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos.

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194586B1 (en) * 1996-09-06 2001-02-27 Eli Lilly And Company Selective sulphonation of the primary alcohol of a diol containing both primary and secondary alcohols
WO1999065894A1 (en) 1998-06-17 1999-12-23 Eisai Co., Ltd. Macrocyclic analogs and methods of their use and preparation
US6214865B1 (en) 1998-06-17 2001-04-10 Eisai Co., Ltd. Macrocyclic analogs and methods of their use and preparation
US6365759B1 (en) 1998-06-17 2002-04-02 Eisai Co., Ltd. Intermediate compounds for preparing macrocylcic analogs
US6469182B1 (en) 1998-06-17 2002-10-22 Eisai Co., Ltd. Intermediates in the preparation of macrocyclic analogs
US8148554B2 (en) 1998-06-17 2012-04-03 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
WO2005118565A1 (en) 2004-06-03 2005-12-15 Eisai Co., Ltd. Intermediates for the preparation of halichondrin b
US20070244187A1 (en) * 2004-06-03 2007-10-18 Eisai Co., Ltd Intermediates for the Preparation of Halichondrin B
US7982060B2 (en) 2004-06-03 2011-07-19 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of Halichondrin B
WO2011094339A1 (en) 2010-01-26 2011-08-04 Eisai R&D Management Co., Ltd. Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
EP2521717B1 (en) 2010-02-10 2013-05-22 Sandoz AG Method for the preparation of rivaroxaban

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
"Advanced Organic Chemistry", March 1992, JOHN WILEY AND SONS, pages: 351 - 357
"Greene's Protective Groups in Organic Synthesis", 2006, WILEY-INTERSCIENCE
"Pharmaceutical Salts: Properties, Selection, and Use", 2008, WILEY-VCH
ALLEPUZ ANA C., BADORREY RAMóN, DíAZ-DE-VILLEGAS MARíA D., GáLVEZ JOSé A.: "Asymmetric Synthesis of ES-285, an Anticancer Agent Isolated from Marine Sources", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, vol. 2009, no. 35, 1 December 2009 (2009-12-01), DE , pages 6172 - 6178, XP093033253, ISSN: 1434-193X, DOI: 10.1002/ejoc.200900828
AUSTAD ET AL., SYN. LETT., vol. 24, no. 3, 2013, pages 327 - 332
AUSTAD ET AL., SYN. LETT., vol. 24, no. 3, 2013, pages 333 - 337
BERGE ET AL.: "J. Pharmaceutical Sciences", vol. 66, 1977, pages: 1 - 19
CHASE ET AL., SYN. LETT., vol. 24, no. 3, 2013, pages 323 - 326
CHEN QIAN, MULZER MICHAEL, SHI PEI, BEUNING PENNY J., COATES GEOFFREY W., O’DOHERTY GEORGE A.: "De Novo Asymmetric Synthesis of Fridamycin E", ORGANIC LETTERS, vol. 13, no. 24, 16 December 2011 (2011-12-16), US , pages 6592 - 6595, XP093033083, ISSN: 1523-7060, DOI: 10.1021/ol203041b
FERNANDES PRISCILLA H., HACKFELD LINDA C., KOZEKOV IVAN D., HODGE RICHARD P., LLOYD R. STEPHEN: "Synthesis and Mutagenesis of the Butadiene-Derived N3 2‘-Deoxyuridine Adducts", CHEMICAL RESEARCH IN TOXICOLOGY, vol. 19, no. 7, 1 July 2006 (2006-07-01), US , pages 968 - 976, XP093033267, ISSN: 0893-228X, DOI: 10.1021/tx060016o
GUILLAUME, M. ; LANG, Y.: "Further improvements of the dibutyl tin oxide-catalyzed regioselective diol tosylation", TETRAHEDRON LETTERS, vol. 51, no. 4, 27 January 2010 (2010-01-27), Amsterdam , NL , pages 579 - 582, XP026815266, ISSN: 0040-4039
MARTINELLI MICHAEL J., NAYYAR NARESH K., MOHER ERIC D., DHOKTE ULHAS P., PAWLAK JOSEPH M., VAIDYANATHAN RAJAPPA: "Dibutyltin Oxide Catalyzed Selective Sulfonylation of α-Chelatable Primary Alcohols", ORGANIC LETTERS, vol. 1, no. 3, 1 August 1999 (1999-08-01), US , pages 447 - 450, XP093033077, ISSN: 1523-7060, DOI: 10.1021/ol990658l
R. SATEESH CHANDRA KUMAR; G. VENKATESWAR REDDY; K. SURESH BABU; J. MADHUSUDANA RAO;: "Stereoselective synthesis of (+)-(8,8a)-perhydro-8-indolizidinol", TETRAHEDRON LETTERS, vol. 52, no. 34, 22 May 2011 (2011-05-22), Amsterdam , NL , pages 4382 - 4384, XP028244255, ISSN: 0040-4039, DOI: 10.1016/j.tetlet.2011.05.102
REBER KEITH P.: "Toward a Synthesis of Hirsutellone B by the Concept of Double Cyclization", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 78, 1 January 2013 (2013-01-01), pages 9584 - 9607, XP093033071
SRIDHAR NARAYAN ET AL: "Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 21, no. 6, 20 January 2011 (2011-01-20), pages 1634 - 1638, XP028169543, ISSN: 0960-894X, [retrieved on 20110125], DOI: 10.1016/J.BMCL.2011.01.097 *
ZHENG W ET AL: "Macrocyclic ketone analogues of halichondrin B", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 14, no. 22, 15 November 2004 (2004-11-15), pages 5551 - 5554, XP004598592, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2004.08.069 *
ZHONG SHI, MONDON MARTINE, LEN CHRISTOPHE: "Synthesis of a novel uridine analogue and its use in attempts to form new cyclonucleosides using ring-closing metathesis", SCIENCE CHINA CHEMISTRY; THE FRONTIERS OF CHEMICAL BIOLOGY AND SYNTHESIS, vol. 53, no. 9, 1 September 2010 (2010-09-01), Sience China Press , pages 1932 - 1936, XP093033260, ISSN: 1674-7291, DOI: 10.1007/s11426-010-4063-3

Also Published As

Publication number Publication date
WO2015085193A1 (en) 2015-06-11
EP3077399B1 (en) 2019-02-20
IL281275B (en) 2021-12-01
BR112016012237B1 (pt) 2023-02-07
US20170298078A1 (en) 2017-10-19
BR112016012237A2 (ru) 2017-08-08
JP2020059739A (ja) 2020-04-16
EP3077399A1 (en) 2016-10-12
US10030032B2 (en) 2018-07-24
US20160176895A1 (en) 2016-06-23
MX370611B (es) 2019-12-18
CA2931788A1 (en) 2015-06-11
ES2723355T3 (es) 2019-08-26
HUE043088T2 (hu) 2019-08-28
MX2016006891A (es) 2017-06-12
MX2019011926A (es) 2019-11-18
US10450324B2 (en) 2019-10-22
IL273736B (en) 2021-03-25
JP6905041B2 (ja) 2021-07-21
US20190010166A1 (en) 2019-01-10
JP6634135B2 (ja) 2020-01-22
US9695188B2 (en) 2017-07-04
IL265640A (en) 2019-05-30
US20150158881A1 (en) 2015-06-11
SG11201604545XA (en) 2016-07-28
CN105916861A (zh) 2016-08-31
JP2019031530A (ja) 2019-02-28
IL245661A0 (en) 2016-06-30
CA2931788C (en) 2022-05-24
US9303039B2 (en) 2016-04-05
IL281275A (en) 2021-04-29
JP2016540752A (ja) 2016-12-28
SG10201805024YA (en) 2018-07-30
IL273736A (en) 2020-05-31
MX2020004855A (es) 2021-07-08
CN105916861B (zh) 2018-12-14
IL265640B (en) 2020-04-30
RU2676486C1 (ru) 2018-12-29
JP6443812B2 (ja) 2018-12-26
EP3077399A4 (en) 2017-05-10

Similar Documents

Publication Publication Date Title
EP3077399B1 (en) Methods useful in the synthesis of halichondrin b analogs
AU2011254654B2 (en) Process for the preparation of chiral triazolones
EP2640730B1 (en) Processes for preparation of everolimus and intermediates thereof
RU2603261C2 (ru) Региоселективное ацилирование рапамицина в положении с-42
CN112047888A (zh) 一种合成恩杂鲁胺的方法
JP2022163113A (ja) プリン誘導体を調製するための方法
TR201901758T4 (tr) Radyoiyodine edilmiş 3-flüoropropil-nor-beta-cit'nin hazırlanması.
CN102159580B (zh) 制备1,6:2,3-双脱水-β-D-吡喃甘露糖的方法
JP6528251B2 (ja) （ｓ）−１−（（２ｒ，３ｒ，４ｓ，５ｓ）−５−アリル−３−メトキシ−４−（トシルメチル）テトラヒドロフラン−２−イル）−３−アミノプロパン−２−オールの結晶性誘導体
US6706888B2 (en) Processes for preparing imidazole derivatives and salts thereof
KR100474228B1 (ko) 파크리탁셀의분리방법
Prashad et al. A practical synthesis of SDZ WAG 994 by selective methylation of N6-cyclohexyladenosine
CN111153844A (zh) 一种依折麦布光学异构体的制备方法
JP2001233890A (ja) スルホニル化ヌクレオシド誘導体
JP2001199993A (ja) ヒドロキシヌクレオシド誘導体

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3077399

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191220

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220216

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230510